Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

Study Group: Oncologists who Treat Hematologic Malignancies (US)(?)

Council Members in this Study Group: 657

This study group may include physicians, care providers, and researchers specializing in internal medicine, cardiology, oncology, dermatology, emergency medicine, family medicine, neurology, obstetrics-gynecology, psychiatry, radiology, nursing, optometry, genetics, and mental health. It may also include experts knowledgeable on diagnostic labs, disease management, medical devices, long term care, surgery centers, health management, pharma, and biotechnology, among others.

Request a survey with this Study Group







Leading Experts in this Study Group

What is a GLG Leader?
Donald Fleming, MD, Division Head of Hematology and Oncology, MEDICAL CENTER OF VINCENNESDonald Fleming, MD
Division Head of Hematology and Oncology
MEDICAL CENTER OF VINCENNES

Donald Fleming, MD, is the Head of Hematology-Oncology at the Medical Center of Vincennes. Previously, Dr. Fleming was a Tenured Professor in the Division of Hematology-Oncology at University of Louisville. He has published over 25 manuscripts in peer-reviewed journals and remains involved in clinical...


60 recent news post(s)
Kenneth Algazy, MD, Clinical Professor of Medicine , University of Pennsylvania School of Medicine - CCKenneth Algazy, MD
Clinical Professor of Medicine
University of Pennsylvania School of Medicine - CC

Kenneth Algazy, MD, is a Clinical Professor of Medicine at University of Pennsylvania School of Medicine. He is also a Section Chief in the Division of Hematology and Oncology at Philadelphia VA Medical Center. Dr. Algazy is involved in clinical trials in lung cancer, and interested in demographics...


341 recent news post(s)
Donald Tsai, MD PhD
Assistant Professor of Medicine
University of Pennsylvania Cancer Center

Donald Tsai, MD, PhD, is an Assistant Professor of Medicine at University of Pennsylvania Cancer Center. Dr. Tsai specializes in the treatment of hematological malignancies such as leukemia, multiple myeloma, lymphoma, Hodgkin's disease, myelodysplastic syndrome (MDS), and bone marrow transplantation....


Related Study Groups

GLG NewsSMAnalyses by this Study Group's Experts(?)

Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
Novo Nordisk: Good try but recombinant activated factor VII did not reach its goal in hemorrhagic stoke | 05-15-2008
Analysis of: Efficacy and Safety of Recombinant Activated Factor VII for Acute Intracerebral Hemorrhage | content.nejm.org
Author: Kenneth Algazy, MD, Clinical Professor of Medicine , University of Pennsylvania School of Medicine - CC

"In summary, rFVIIa reduced hematoma growth but did not reduce the rate of death or severe disability after intracerebral hemorrhage."

GSK: Gutsy but logical clinical trial of Tykerb v Herceptin (Genentech) | 05-13-2008
Analysis of: Glaxo Tests Tykerb vs Herceptin in Early Cancer | www.therapeuticsdaily.com
Author: Kenneth Algazy, MD, Clinical Professor of Medicine , University of Pennsylvania School of Medicine - CC

Glaxo is trying to move Tykerb ahead of Herceptin in a first line/neoajuvant/adjuvant setting in Her2Neu + Breast cancer.

ImClone: Does Morgan Stanley (MS) know something we don't?? | 05-12-2008
Analysis of: US Drug Stocks Edge Higher, But ImClone Falls On Downgrade | news.ino.com
Author: Kenneth Algazy, MD, Clinical Professor of Medicine , University of Pennsylvania School of Medicine - CC

Erbitux was touted to have a positive study in Non Small Cell Lung Cancer (NSCLCA) but all they said was that is was a positive study. No further info at that time but an executive bought a block of stock a few days before the announcement which led to an inevitable rise in the stock price! Does this...

ASA404 approach in treating lung cancer | 05-09-2008
Analysis of: ASA404 begins pivotal trial to explore new approach in treating lung cancer, the leading cause of cancer death | www.pipelinereview.com
Author: Donald Fleming, MD, Division Head of Hematology and Oncology, MEDICAL CENTER OF VINCENNES

ASA404 begins pivotal trial to explore new approach in treating lung cancer ASA404 is a drug that helps chemo treat lung cancer yet eliminate exisiting blood vessels supplying the tumors

May be jumping into phase II too soon | 05-07-2008
Analysis of: Proteolix Initiates Phase 2 Clinical Trial of Carfilzomib in Patients with Relapsed Solid Tumors | www.pipelinereview.com
Author: GLG Expert Contributor

The fact that they had a very small phase I studay of 14 patients only.  This concerns me a bit.  Usualy you enrol at least 30-40 patients in a phase I trial

View All GLG News by members of this Study Group

Most Common Company Types:

  • Academic Medical Center/Hospital or Clinic
  • Office Based Private Practice or Clinic
  • Non-Academic Community Hospital or Clinic

Most Common Job Types:

  • Physician - Attending Physician
  • Physician - Director
  • Owner
  • Physician - Division Head

GLG's 750+ Clients Include:

40 of the leading 50
global mutual funds
15 of the leading 20
global banks
8 of the leading 10
private equity firms
90%+ client subscription renewal rate

Analytics